Xunbao Duan

This inventor holds 11 USPTO granted patents and 1 published patent application, plus 2 CIPO patents and 2 EPO patents. Top assignee: Regeneron Pharmaceuticals, Inc.. Active years: 2014-2024.

USPTO Granted Patents = 11 (Patent Applications = 1)

% Patents Active = 100.0

CIPO Patents = 2 (Patent Applications = 2)

EPO Patents = 2 (Patent Applications = 4)

Average Co-Inventor Count = 3.3

ph-index = 4

Forward Citations = 61(Granted Patents)

Location History:

Maple Glen, PA (US) (2016)
Ambler, PA (US) (2018)
Horsham, PA (US) (2014 - 2023)
Brewster, NY (US) (2024)

Company Filing History:

11 out of 1,477

Regeneron Pharmaceuticals, Inc.

patents

Years Active: 2014-2024

Loading Chart...

11 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12037411 - Antibodies, and bispecific antigen-binding molecules that bind HER2 and/or APLP2, conjugates, and uses thereof (2024-07-16),

2. 11771762 - Anti-ErbB3 antibodies and uses thereof (2023-10-03),

3. 10632194 - Anti-ErbB3 antibodies and uses thereof (2020-04-28),

4. 10125188 - Human antibodies to respiratory syncytial virus F protein and methods of use thereof (2018-11-13),

5. 9827310 - Anti-ErbB3 antibodies and uses thereof (2017-11-28),

6. 9533039 - Methods of treating systemic lupus erythematosus (SLE) using anti-CD48 antibodies (2017-01-03),

7. 9447173 - Human antibodies to respiratory syncytial virus F protein and methods of use thereof (2016-09-20),

8. 9284380 - Anti-ErbB3 antibodies and uses thereof (2016-03-15),

9. 9273143 - Methods and compositions comprising a combination of an anti-ErbB3 antibody and an anti-EGFR antibody (2016-03-01),

10. 9228014 - Antibodies capable of blocking the interaction between CD48 and a CD48 receptor (2016-01-05),

11. 8791244 - Anti-ErbB3 antibodies and uses thereof (2014-07-29),

Title: Innovations of Xunbao Duan in Cancer Treatment

Introduction

Xunbao Duan is a prominent inventor based in Horsham, PA (US), known for his significant contributions to the field of cancer treatment. With a total of 11 patents, his work primarily focuses on developing novel antibodies and bispecific antigen-binding molecules that target specific proteins associated with aggressive tumor growth.

Latest Patents

Duan's latest patents include groundbreaking inventions related to antibodies and bispecific antigen-binding molecules that bind to HER2 and/or APLP2. The human epidermal growth factor 2 (HER2) is a critical protein expressed in breast cancer cells, and its expression is often correlated with aggressive tumor growth. His inventions provide novel full-length human (IgG) antibodies that specifically bind to human HER2 and APLP2. Additionally, he has developed bispecific antibodies that can bind to both HER2 and APLP2, facilitating the internalization and degradation of HER2 in the presence of HER2-expressing tumors. These bispecific antibodies are particularly useful for treating breast cancers, including those classified as IHC2+. Furthermore, Duan's patents also encompass anti-HER2 antibody drug conjugates that inhibit tumor growth in vivo.

Career Highlights

Xunbao Duan is currently employed at Regeneron Pharmaceuticals, Inc., where he continues to innovate in the field of cancer therapeutics. His work has been instrumental in advancing the understanding and treatment of various cancers, particularly those associated with the HER2 protein.

Collaborations

Duan collaborates with notable colleagues, including Douglas MacDonald and Christopher Daly, to further enhance the impact of his research and inventions in the pharmaceutical industry.

Conclusion

Xunbao Duan's innovative work in developing targeted therapies for cancer exemplifies the potential of scientific research to improve treatment outcomes for patients. His contributions to the field are paving the way for more effective cancer therapies.